ATLANTA, GA -- (Marketwired) -- 12/23/13 -- VolitionRx Ltd. (OTCQB: VNRX) (the "Company") today announces that it has engaged the investor relations services of MissionIR. Through a network of investor-oriented sites and full suite of investor awareness services, MissionIR broadens the influence of publicly traded companies and enhances their ability to attract growth capital as well as improve shareholder value.
"VolitionRx is developing a blood-based cancer diagnostics tool that in preclinical trials has demonstrated tremendous potential to change the landscape of colorectal cancer screening," stated Sherri Franklin, Director of Marketing at MissionIR. "As the Company continues its focus on ongoing clinical trials of this product, MissionIR will work to increase VolitionRx's visibility among the investment community and strengthen dialogue with existing Company shareholders. We're excited to be a part of VolitionRx's future."
Cameron Reynolds, CEO of VolitionRx, stated, "This new partnership with MissionIR will enhance our current investor relations initiatives and help us to execute a strategic campaign to better reach and communicate with our shareholders. Additionally, as we continue with the advancement of our cancer diagnostic tests, we look forward to working with MissionIR's team to maximize product exposure and attain our short-term and long-term goals. MissionIR is providing a much needed service not only to VolitionRx, but to the broader small-cap market."
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. Through a full suite of investor relations and consultancy services, we help public companies develop and execute a strategic investor awareness plan as we've done for hundreds of others. Whether it's capital raising, increasing awareness among the financial community, or enhancing corporate communications, we offer a variety of solutions to meet the objectives of our clients.
For more information, visit www.MissionIR.com
About VolitionRx Ltd.
VolitionRx is a life sciences company focused on developing blood-based diagnostic tests for different types of cancer. The tests are based on the science of Nucleosomics which is the practice of identifying and measuring nucleosomes in the bloodstream -- an indication that cancer is present.
VolitionRx's goal is to make the tests as common and simple to use, for both patients and doctors, as existing diabetic and cholesterol blood tests. VolitionRx's research and development activities are currently centred in Belgium as the company focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and ultimately, worldwide.
For more information, visit www.VNRX.MissionIR.com
This Press Release may contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements reflect the Company's current beliefs and are based upon information currently available to it. Accordingly, such forward-looking statements involve known and unknown risks, uncertainties and other factors which could cause the Company's actual results, performance or achievements to differ materially from those expressed in or implied by such statements. The Company undertakes no obligation to update or advise in the event of any change, addition or alteration to the information included in this Press Release including such forward-looking statements.
Contact: Mission Investor Relations Sherri Franklin http://www.MissionIR.com 404-941-8975 Investors@MissionIR.com
Source: VolitionRx Ltd.